David Drewry

David Drewry

SGC UNC

Drewry

David Drewry

(919) 962-5349

Biography

David Drewry is a renowned leader in the medicinal chemistry of protein kinases and is one of the principal architects of the research strategy at the SGC-UNC to build an open and collaborative research network to promote target discovery. He previously enjoyed more than 24 years as a medicinal chemist with GlaxoSmithKline and legacy companies, where he led teams working across the preclinical spectrum of drug discovery. His research interests include the art and science of medicinal chemistry, kinase inhibitor design, utilization of annotated sets of kinase inhibitors to build understanding of signaling networks and precompetitive chemical biology to facilitate target identification. After earning a Bachelor’s of Science degree, cum laude, in chemistry from Yale University, Drewry earned his doctorate at the University of California, Berkeley in the laboratory of Paul Bartlett, working on the design, synthesis and mechanistic studies of zinc protease inhibitors. Drewry is currently the head of chemistry at Meryx Pharmaceuticals, a biotech startup focused on small-molecule inhibitors of Mer kinase that was a spinoff from the UNC Eshelman School of Pharmacy. Drewry enjoys running, reading and relaxing with his family at local restaurants, the movie theater or in the kitchen playing board games.

2021

Targeting Never-In-Mitosis-A Related Kinase 5 in Cancer: A Review.

Matossian MD, Wells CI, Zuercher WJ, Collins-Burow BM, Drewry DH, Burow ME

Curr Med Chem. 2021-3-21 . .doi: 10.2174/0929867328666210322101749

PMID: 33749548

Development of a potent and selective chemical probe for the pleiotropic kinase CK2.

Wells CI, Drewry DH, Pickett JE, Tjaden A, Krämer A, Müller S, Gyenis L, Menyhart D, Litchfield DW, Knapp S, Axtman AD

Cell Chem Biol. 2021-1-11 . .doi: 10.1016/j.chembiol.2020.12.013

PMID: 33484635

The Kinase Chemogenomic Set (KCGS): An Open Science Resource for Kinase Vulnerability Identification.

Wells CI, Al-Ali H, Andrews DM, Asquith CRM, Axtman AD, Dikic I, Ebner D, Ettmayer P, Fischer C, Frederiksen M, Futrell RE, Gray NS, Hatch SB, Knapp S, Lücking U, Michaelides M, Mills CE, Müller S, Owen D, Picado A, Saikatendu KS, Schröder M, Stolz A, Tellechea M, Turunen BJ, Vilar S, Wang J, Zuercher WJ, Willson TM, Drewry DH

Int J Mol Sci. 2021-1-8 . 22(2): .doi: 10.3390/ijms22020566

PMID: 33429995

2020

A Chemical Probe for Dark Kinase STK17B Derives Its Potency and High Selectivity through a Unique P-Loop Conformation.

Picado A, Chaikuad A, Wells CI, Shrestha S, Zuercher WJ, Pickett JE, Kwarcinski FE, Sinha P, de Silva CS, Zutshi R, Liu S, Kannan N, Knapp S, Drewry DH, Willson TM

J Med Chem. 2020-11-20 . .doi: 10.1021/acs.jmedchem.0c01174

PMID: 33215924

Crystal Structure and Inhibitor Identifications Reveal Targeting Opportunity for the Atypical MAPK Kinase ERK3.

Schröder M, Filippakopoulos P, Schwalm MP, Ferrer CA, Drewry DH, Knapp S, Chaikuad A

Int J Mol Sci. 2020-10-26 . 21(21): .doi: 10.3390/ijms21217953

PMID: 33114754

PKIS deep dive yields a chemical starting point for dark kinases and a cell active BRSK2 inhibitor.

Tamir TY, Drewry DH, Wells C, Major MB, Axtman AD

Sci Rep. 2020-9-28 . 10(1):15826 .doi: 10.1038/s41598-020-72869-9

PMID: 32985588

A novel screening approach comparing kinase activity of small molecule inhibitors with similar molecular structures and distinct biologic effects in triple-negative breast cancer to identify targetable signaling pathways.

Matossian MD, Burks HE, Elliott S, Hoang VT, Zuercher WJ, Wells C, Drewry DH, Kapadia N, Chang T, Yan T, Windsor GO, Nguyen K, Fang F, Nephew KP, Buechlein A, Rusch DB, Sabol RA, Ucar DA, Zabaleta J, Miele L, Bunnell BA, Collins-Burow BM, Burow ME

Anticancer Drugs. 2020-8-17 . 31(8):759-775 .doi: 10.1097/CAD.0000000000000962

PMID: 32796402

Synergistic drug combinations and machine learning for drug repurposing in chordoma.

Anderson E, Havener TM, Zorn KM, Foil DH, Lane TR, Capuzzi SJ, Morris D, Hickey AJ, Drewry DH, Ekins S

Sci Rep. 2020-7-31 . 10(1):12982 .doi: 10.1038/s41598-020-70026-w

PMID: 32737414

Identifying the target of an antiparasitic compound in Toxoplasma using thermal proteome profiling.

Herneisen AL, Sidik SM, Markus BM, Drewry DH, Zuercher WJ, Lourido S

ACS Chem. Biol.. 2020-6-29 . .doi: 10.1021/acschembio.0c00369

PMID: 32597628